Scholarlink

Introduction <p>Generalized pustular psoriasis (GPP) is a rare, severe, and chronic inflammatory skin disease characterized by widespread pustules that leads to unpredictable and potentially serious disease flares. Information regarding treatment status for GPP and treatment patterns for flares is important but limited as a result of the rarity of the condition. We conducted a 10-year, retrospective, longitudinal chart review of treatment patterns at GPP referral hospitals in Japan.</p> Methods <p>Eligible patients with GPP had at least 6&#xa0;months of continuous observation data within 10&#xa0;years after the date of protocol approval. Data were collected from patient records and annual patient reports. Patient characteristics and treatment details, including in relation to flare occurrence, were analyzed.</p> Results <p>The median age of patients (<i>N</i> = 205) was 53&#xa0;years; 48.3% were female and most had mild or moderate GPP (66.8%). Patients commonly received nonbiologic systemic therapy (86.3%) and a similar proportion received biologics (79.5%); 95.1% received topical treatment and 22.4% received systemic adrenal corticosteroids. Use of nonbiologic systemic therapy decreased, and use of biologics increased, over the study period. During the observation period, the proportion of patients receiving biologic therapy increased after a flare (from 41.4% receiving biologics when flares occurred to 62.9% initiating a new biologic post flare).</p> Conclusion <p>In Japanese clinical practice, the evolution of treatment practices for GPP has seen an increased use of biologic therapies over time. Biologic use was common after flares; however, some flares occurred during biologic therapy, indicating a need for improved treatment options to maintain stable disease and prevent flares.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment Status for Generalized Pustular Psoriasis in Japanese Patients: A Retrospective Chart Review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月19日

查看全文
  • Yukari Okubo,
  • Ryuhei Okuyama,
  • Shinichi Imafuku,
  • Yayoi Tada,
  • Keiichi Yamanaka,
  • Kazumitsu Sugiura,
  • Yukie Yamaguchi,
  • Masahito Yasuda,
  • Wataru Sakamoto,
  • Morihisa Saitoh,
  • Akimichi Morita,
  • Akimichi Morita,
  • Ryuhei Okuyama,
  • Kenji Kabashima,
  • Yukie Yamaguchi,
  • Koji Masuda,
  • Yoko Muzutani,
  • Keiichi Yamanaka,
  • Takuro Kanekura,
  • Shigeto Yanagihara,
  • Chiharu Tateishi,
  • Yukari Okubo,
  • Yayoi Tada,
  • Tetsuya Honda,
  • Satoshi Fukushima,
  • Kazuki Yatsuzuka,
  • Takuya Miyagi,
  • Masahito Yasuda,
  • Emi Yokoyama,
  • Mayumi Komine,
  • Nobuo Kanazawa,
  • Kazumitsu Sugiura,
  • Masahiro Amano,
  • Daisuke Watabe,
  • Koremasa Hayama,
  • Hitoshi Tsuchihashi,
  • Masaru Honma,
  • Masatoshi Abe,
  • Hajime Iizuka,
  • Akihiko Asahina

摘要

Introduction

Generalized pustular psoriasis (GPP) is a rare, severe, and chronic inflammatory skin disease characterized by widespread pustules that leads to unpredictable and potentially serious disease flares. Information regarding treatment status for GPP and treatment patterns for flares is important but limited as a result of the rarity of the condition. We conducted a 10-year, retrospective, longitudinal chart review of treatment patterns at GPP referral hospitals in Japan.

Methods

Eligible patients with GPP had at least 6 months of continuous observation data within 10 years after the date of protocol approval. Data were collected from patient records and annual patient reports. Patient characteristics and treatment details, including in relation to flare occurrence, were analyzed.

Results

The median age of patients (N = 205) was 53 years; 48.3% were female and most had mild or moderate GPP (66.8%). Patients commonly received nonbiologic systemic therapy (86.3%) and a similar proportion received biologics (79.5%); 95.1% received topical treatment and 22.4% received systemic adrenal corticosteroids. Use of nonbiologic systemic therapy decreased, and use of biologics increased, over the study period. During the observation period, the proportion of patients receiving biologic therapy increased after a flare (from 41.4% receiving biologics when flares occurred to 62.9% initiating a new biologic post flare).

Conclusion

In Japanese clinical practice, the evolution of treatment practices for GPP has seen an increased use of biologic therapies over time. Biologic use was common after flares; however, some flares occurred during biologic therapy, indicating a need for improved treatment options to maintain stable disease and prevent flares.